Unlabelled: Multiple myeloma (MM) is the second most common haematological malignancy, the diagnosis of which has doubled in recent years. Immune thrombocytopenia consists of isolated thrombocytopenia secondary to antibody mediated peripheral platelet destruction. In most cases, there is no identifiable cause (primary immune thrombocytopenia). Its association with multiple myeloma is rare. Early recognition of this association is essential for raising awareness among clinicians, allowing for a rapid differential diagnosis and therapeutic optimization, reducing side effects and improving prognosis. Thus, we present a clinical case of concomitant immune thrombocytopenia and MM, whose initial presentation was thrombocytopenia. This clinical case is the first case among thirteen described in the literature in which chemotherapy was the initial treatment for both pathologies, as seen in this review.
Learning Points: Multiple myeloma is the second most common haematological malignancy and is associated with a broad group of pathologies, including, in some cases, autoimmune manifestations. Thrombocytopenia in multiple myeloma is common due to therapy or bone marrow plasmacytosis, but the association of immune thrombocytopenia with multiple myeloma is rare.Raising clinicians' awareness of the association of multiple myeloma with immune thrombocytopenia is essential for a rapid differential diagnosis. This can alter therapeutic possibilities and consequent patient prognoses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623356 | PMC |
http://dx.doi.org/10.12890/2024_004981 | DOI Listing |
Int J Biol Macromol
December 2024
Faculty of Medical Engineering, National University of Science and Technology Politehnica Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; Advanced Polymer Materials Group, University Politehnica of Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; ebio-Hub Research Centre, University Politehnica of Bucharest-Campus, Iuliu Maniu 6, 061344 Bucharest, Romania. Electronic address:
Multiple myeloma (MM), a hematological malignancy which affects the monoclonal plasma cells in the bone marrow, is in rising incidence around the world, accounting for approximately 2 % of newly diagnosed cancer cases in the US, Australia, and Western Europe. Despite the progress made in the last few years in the available therapeutic options (e.g.
View Article and Find Full Text PDFQJM
December 2024
Assistant Professor, All India Institute of Medical Sciences, Delhi, 110029, India.
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Medical Sciences, Human Genome Centre, Health Campus, Kelantan, Malaysia.
Multiple myeloma (MM), a clonal B-cell neoplasia, is an incurable and heterogeneous disease where survival ranges from a few months to more than 10 years. The clinical heterogeneity of MM arises from multiple genomic events that result in tumour development and progression. Recurring genomic abnormalities including cytogenetic abnormalities, gene mutations and abnormal gene expression profiles in myeloma cells have a strong prognostic power.
View Article and Find Full Text PDFIran Biomed J
December 2024
Department of Hematology and Blood Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Sci Rep
December 2024
Faculty of Medicine, University of Social Sciences in Łódź, 90-113, Łódź, Poland.
Due to its course, multiple myeloma may negatively affect the functioning of patients. Different treatment methods are also associated with patients' varying perception of their health condition. The purpose of this study is to determine the disease-specific complaints among multiple myeloma patients during selected treatment methods-chemotherapy, autologous hematopoietic stem cell transplantation, and supportive therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!